Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 20/20 | 0.67 |
| ▸ | PRKCD | Q05655 | 17/20 | 0.62 |
| ▸ | LYN | P07948 | 2/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | HCK | P08631 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | PRKCH | P24723 | 1/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518088 | 1.00 | PRKCQ (0.67) | PRKCQPRKCDLYNLCKFYN | |
| SCHEMBL5531751 | 0.91 | PRKCQ (0.67) | PRKCQPRKCDLYNLCKFYN | |
| SCHEMBL5529992 | 0.91 | PRKCQ (0.67) | PRKCQPRKCDLYNLCKFYN | |
| SCHEMBL5529989 | 0.91 | PRKCQ (0.67) | PRKCQPRKCDLYNLCKFYN | |
| SCHEMBL5531744 | 0.91 | PRKCQ (0.67) | PRKCQPRKCDLYNLCKFYN | |
| SCHEMBL4952537 | 0.91 | PRKCQ (0.72) | PRKCQPRKCDLYN | |
| SCHEMBL4952532 | 0.91 | PRKCQ (0.72) | PRKCQPRKCDLYN | |
| SCHEMBL5520576 | 0.89 | PRKCQ (0.64) | PRKCQPRKCDLYNLCKFYN | |
| SCHEMBL5520579 | 0.89 | PRKCQ (0.64) | PRKCQPRKCDLYNLCKFYN | |
| SCHEMBL5531749 | 0.86 | PRKCQ (0.70) | PRKCQPRKCDLYNLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | MAP4K2, CNKSR1, MAP3K1 | PRKCQ 286/4885PRKCD 356/4885LYN 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.